17-10-5　ⓔ文献

  1. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (Swerdlow SH, Campo E, et al), IARC press, 2017; 39–53.

  2. Scherber, R, Dueck AC, et al: The Myeloproliferative Neoplasm Symptom Assessment Form (MPN–SAF): international prospective validation and reliability trial in 402 patients. Blood, 2011; 118: 401–408.

  3. Takenaka K, Shimoda K, et al: Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17–year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Int J Hematol, 2017; 105: 59–69.

  4. Cervantes F, Dupriez B, et al: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009; 113: 2895–2901.

  5. Passamonti F, Cervantes F, et al: Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood, 2010; 116: 2857–2858.

  6. Gangat N, Caramazza D, et al: DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol, 2011; 29: 392–397.

  7. 日本血液学会編：造血器腫瘍診療ガイドライン2018年版，金原出版，2018.

  8. Ballen, KK, Shrestha S, et al: Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant, 2010; 16: 358–367.

  9. Verstovsek S, Mesa RA, et al: A double–blind, placebo–controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012; 366: 799–807.

  10. Harrison C, Kiladjian JJ, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Eng J Med, 2012; 366: 787–798.

  11. Verstovsek S, Mesa RA, et al: Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2–year follow–up of COMFORT–I. Haematologica, 2013; 98: 1865–1871.

  12. Passamonti F, Maffioli M, et al: Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 2014; 123: 1833–1835.